Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

MedX Health Corp. Announces Regulatory Clearance for its SIAscopy Medical Devices in New Zealand

MedX Health Corp.
Posted on: 28 Feb 18

MedX Health Corp. (“MedX”) (TSX-V: MDX) announced today it has received regulatory clearance from the New Zealand Medicines and Medical Devices safety authority (Medsafe WAND) to sell its SIAscope medical device in New Zealand.

New Zealand has the highest rate of melanoma skin cancer in the world – eclipsing Australia as the most dangerous place to be exposed to the sun, according to new research published in the Journal of Investigative Dermatology. “MedX believes it can greatly reduce the incidence of skin cancer mortality through early detection and is committed to entering markets that have a high incidence of skin cancer to address this life-threatening issue,” said Rob von der Porten, President & CEO.

“MedX will develop the New Zealand market by establishing a strong, local partner to distribute our rapid skin assessment technology, as we have done in other international markets. Our experience is that securing a partner with local market knowledge and relationships is key to entering and growing our sales in that market,” added Mr. von der Porten.

About MedX

MedX, headquartered in Mississauga, Ontario, is a leading medical device company focused on skin cancer with its SIAscopy technology. This technology is imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. The devices are sold to physicians and clinics, as well as being deployed in pharmacies and remote clinics from where the images are sent to dermatologists who perform a diagnosis. These products are Health Canada, FDA (US), ARTG and CE approved for use in Canada, the US, Australia, the European Union and Turkey. SIAMETRICS™ is a unique product used in a specialized market for research into the clinical effectiveness of medical treatments of certain skin conditions. MedX also designs, manufactures and distributes quality laser and light therapy technologies for use in numerous medical settings, approved in major jurisdictions, to provide drug free and non-invasive treatment of tissue damage and pain. For more information and a complete profile of MedX and its products visit www.medxhealth.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20180228005178/en/

Business Wire
www.businesswire.com

Last updated on: 28/02/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.